ANNOUNCEMENT DETAILS

Stay updated on Malaysian bonds and sukuk.

ANNOUNCEMENT DATE
:
12-Nov-2026
CATEGORY
:
RATING ANNOUNCEMENT
SUB-CATEGORY
:
RATING ANNOUNCEMENT
TITLE
:
Point Zone (M) Sdn Bhd
ISSUER NAME
:
POINT ZONE (M) SDN BHD
DESCRIPTION
:
CONTENT
:
MARC RATINGS AFFIRMS POINT ZONE'S AAIS(cg) RATING

MARC Ratings has affirmed its AAIS(cg)/Stable rating on Point Zone (M) Sdn Bhd's Sukuk Wakalah Programme. The rating reflects the credit strength of the guarantor, KPJ Healthcare Berhad (KPJ), with Point Zone serving solely as the funding vehicle for the sukuk issuance.

The rating affirmation is underpinned by KPJ's strong business profile, anchored by its leading position in Malaysia's private healthcare sector and established brand. Its solid operating track record, comprising 30 hospitals with more than 4,000 licensed beds and an estimated 20% market share by bed count, supports resilient revenue growth and robust cash flow generation. The rating also considers KPJ's moderate leverage and sound liquidity position. These strengths are moderated by the funding and execution requirements of its sizeable expansion programme, elevated medical cost inflation, and regulatory and contingent liability risks.

KPJ's operating performance in 2025 was underpinned by sustained growth in patient volumes. Total patient visits reached approximately 3.3 million, with inpatient admissions increasing by 0.8% to 379,342, outpatient visits rising by 4.0% to approximately 2.9 million, and surgical procedures growing by 7.3% to about 117,000. In 1H2026, total patient visits increased by approximately 5.0% y-o-y to 1.7 million. Inpatient admissions rose to around 191,000 from 180,000, while outpatient visits and surgical procedures increased to 1.46 million and approximately 59,000, respectively. The bed occupancy rate improved to 66% from 64% in 2025, reflecting stronger utilisation across the hospital network. These trends supported a 9.2% increase in revenue to RM4.26 billion in 2025. In 1H2026, revenue rose by 12.8% y-o-y to RM2.25 billion, while EBITDA increased by 11.4% to RM513.6 million. Longer-term growth remains supported by favourable demographics, the rising prevalence of non-communicable diseases, higher healthcare e
ATTACHMENT
:
SOURCE
:
BURSA